Feed QGEN
Market cap
$9.59B
Enterprise value
$10.5B
P/E
23.4x
Forward P/E
19.1x
PEG
0.1x
P/S
4.6x
P/FCF
21.4x
EV/EBITDA
14.2x
ROIC
8.9%
Gross margin
61.8%
Net margin
19.5%
Dividend yield
0.75%
Payout ratio
17.6%
Net debt/EBITDA
1.2x
Beta
0.61
Free float
99.4%

About the company

Qiagen N.V. (QGEN) is a Dutch company specializing in providing innovative diagnostic tests and technologies in the field of molecular biology. With a broad portfolio of products and services including tests for genetic mutations, infectious disease diagnostics, and analytical tools for genetic material research, Qiagen is one of the leading providers of diagnostic solutions in the market. The company focuses on providing accurate, reliable, and fast diagnostic tests that assist physicians and researchers in identifying and treating diseases. Qiagen also invests in innovation and the development of new diagnostic technologies to continuously improve patient diagnosis and treatment. Qiagen N.V. (QGEN) shares could be suitable for investors looking to invest in biotechnology companies with a focus on molecular diagnostics and innovative research and development in the healthcare sector.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Jon Pratt

Employees

5,500

Headquarters

Venlo

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.